Accuray (ARAY) Getting Somewhat Favorable Media Coverage, Analysis Shows

News coverage about Accuray (NASDAQ:ARAY) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accuray earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 47.4297186820934 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

Accuray (ARAY) traded down 3.09% during midday trading on Monday, hitting $4.70. The stock had a trading volume of 654,997 shares. The stock’s market cap is $390.94 million. The company has a 50-day moving average of $4.30 and a 200-day moving average of $4.31. Accuray has a 1-year low of $3.60 and a 1-year high of $6.00.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. The company had revenue of $91.00 million during the quarter, compared to the consensus estimate of $88.26 million. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.91%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.12) earnings per share. Equities research analysts forecast that Accuray will post ($0.24) EPS for the current year.

A number of equities research analysts recently weighed in on the company. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Zacks Investment Research cut Accuray from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Accuray in a report on Thursday, August 24th. Cowen and Company reaffirmed a “buy” rating and set a $9.00 price target on shares of Accuray in a report on Friday. Finally, Jefferies Group LLC dropped their price target on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $6.29.

TRADEMARK VIOLATION NOTICE: “Accuray (ARAY) Getting Somewhat Favorable Media Coverage, Analysis Shows” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/10/30/accuray-aray-getting-somewhat-favorable-media-coverage-analysis-shows.html.

In other news, COO Kelly Londy sold 99,136 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is currently owned by corporate insiders.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

What are top analysts saying about Accuray Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accuray Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit